Autopsy report · NCT01302899

To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“In consequence of termination of ALTITUDE. A number of studies were continued in consultation with the Altitude Data Monitoring Committee.”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 11 months before it stopped.
8 participants enrolled.
Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Novartis Pharmaceuticals
Sponsor type: Industry
Conditions: Non-diabetic Nephropathy
Interventions: Aliskiren; Placebo to Aliskiren; Hydrochlorothiazide (HCTZ); Placebo to Hydrochlorothiazide (HCTZ); Ramipril
Participants: 8
Sites: 2
Countries: Netherlands

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.